- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03029156
Effectiveness of the Aeroneb in Acute Severe Asthma
Effectiveness of the Aeroneb Compared to a Jet Nebulizer Fort the Delivery of Bronchodilator Therapy of Acute Severe Asthma
Background: The bronchodilator therapy is an essential component of the management of asthma exacerbation. The delivery of bronchodilators to the lungs in asthma exacerbations is usually achieved through nebulization (creating small particles to be inhaled). The commonly used nebulizer device is a small volume jet nebulizer which has not been consistently reliable in delivering bronchodilator therapy. The Aeroneb nebulizer device is a FDA approved device which produces consistently respirable sized particles which could potentially result in better bronchodilator effect than the standard jet nebulizer.
Aim: To study whether the Aeroneb nebulizer is more effective than a small volume jet nebulizer in delivering bronchodilators during a severe asthma exacerbation.
Experimental design: Patients will be randomized (like a flip of a coin) to receive bronchodilator therapy as per the emergency room protocol either via small volume jet nebulizer or Aeroneb nebulizer.
Subjects: Adult patients between age of 18 and 55 years who present to the emergency room with severe asthma exacerbation with peak expiratory flow rate <50% of predicted.
Study procedure: When enrolled in the study and after randomization, we will then collect data that is standard for the hospital like heart rate, blood pressure and breathing indices and also some non-routine things like some scoring scales for shortness of breath and serial measurements of peak expiratory flow rate. We anticipate that the Aeroneb device will be more effective in delivering bronchodilator medication and thus more effective in managing asthma exacerbations.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
- Patients presenting with acute severe asthma exacerbations to the emergency room will be screened by the PI, co-investigator or research coordinator to determine their eligibility based on the inclusion and exclusion criteria.
- Clinically indicated treatment must not be delayed for a research-related reason so patients will still be eligible for enrollment after receiving initial bronchodilator therapy as long as their PEFR remains <50% of predicted and enrollment occurs within 90 minutes of the ER arrival time.
- The initial part of the consent process will cover the essential elements of the informed consent in a concise manner to ensure a timely process
- Eligible patients will be randomized using the concealed envelope method to either the intervention arm or the control arm. The randomization should take place within 90 minutes of ER arrival, however, every effort will be made to enroll the patient as soon as possible; patients will be enrolled as long as their PEFR is less than 50% of predicted regardless of the number of bronchodilator treatments they received prior to randomization.
- The assignment will be blinded to the recording investigator and the treating physician but not to the patient or the nurse or respiratory therapist who is administering the nebulization. In order to avoid any delay in administering the treatments, the sets of Aeroneb nebulizer and small volume jet nebulizer will be stored in identical boxes and will be readily available in the ER.
In order to blind the treating physician and the recording investigator, a sign "treatment in progress" will be displayed at the outdoor of the ER room when the patient is getting the bronchodilator treatment. The nebulizer devices will be placed in the box between the bronchodilator treatment sessions. The physician and the recording investigator will be asked if possible to see the patients only when the sign is taken off the outdoor.
- Once assigned, all the bronchodilator treatments in the ER will be administered using the nebulizer device assigned to that patient.
- The Peak flow and FEV1 will be measured using Spirometer (micro I). Both values will be obtained through the same exhalation maneuver.
- Patient will be treated and managed according to the asthma ER adult protocol or as directed by the ER physician who is in charge of patient's care
- After the study procedures have been performed and the subject is determined to be in stable condition and have the capacity to make medical decisions, the investigator will approach the subject again and review all the elements of the ICF again with the subject. The collected data will be used only if the subject signs both parts of the informed consent.
- Within two weeks of the subject participation, the research team will conduct a phone interview with the subject to obtain their feedback on the study procedures and mainly on the informed consent process. The phone interview questionnaire is included in the supplement
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Tufts Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Acute asthma exacerbations presenting to the emergency room
- Peak expiratory flow rate at presentation <40% of predicted
- Enrolment within 90 minutes of the arrival to the ER
- Age 18-55 years old
Exclusion Criteria:
- History of chronic obstructive pulmonary disease
- Clinical evidence to suggest a non-asthmatic cause of bronchospasm as determined by the treating physician
- Clinical evidence of acute coronary syndrome
- Respiratory failure requiring mechanical ventilation either invasive or non-invasive
- Tachyarrhythmia other than sinus
- Agitated or uncooperative
- Inability to provide informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Small volume jet nebulizer
Administration of bronchodilator through small volume jet nebulizer.
The nebulized solution contains ipratropium / albuterol.
|
The bronchodilators will be administered via small volume jet nebulizer
|
Experimental: Aeroneb nebulizer
Administration of bronchodilator via Aeroneb nebulizer.
The nebulized solution contains ipratropium / albuterol.
|
The Aeroneb Nebulizer System is a portable medical device for single patient use that is intended to aerosolize physician-prescribed solutions for inhalation to patients on and off ventilation. The Aeroneb Adapter is an accessory specific to the Aeroneb Nebulizer. It facilitates intermittent and continuous nebulization and optional supply of supplemental oxygen to adult patients in hospital use environments via a mouthpiece or aerosol mask. The Aeroneb Nebulizer System and Adapter are FDA approved devices for nebulizing solutions including bronchodilators (albuterol and ipratropium).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage Change in Mean of Peak Expiratory Flow Rate (PEFR) Percentage of Predicted Baseline at 30 Minutes After the Initial Bronchodilator Treatment
Time Frame: 30 minutes
|
Peak expiratory flow rate is the maximum flow rate generated during a forceful exhalation, starting from full inspiration.
|
30 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage Change in the PEFR Percentage of Predicted Baseline to Disposition
Time Frame: Initial bronchodilator treatment to disposition, an average of 4 hours
|
Change in the PEFR percent predicted from the initial bronchodilator treatment in the Aeroneb group compared to the small volume jet nebulizer group.
|
Initial bronchodilator treatment to disposition, an average of 4 hours
|
Percentage Change in the Forced Expiratory Volume (FEV1) Percentage of Predicted Baseline to Disposition
Time Frame: initial bronchodilator treatment to disposition, an average of 4 hours
|
Forced expiratory volume refers to the volume of air that an individual can exhale during a forced breath in 1 second.
|
initial bronchodilator treatment to disposition, an average of 4 hours
|
Change in the Borg-Dyspnea Score From Baseline to Disposition
Time Frame: initial bronchodilator treatment to disposition, an average of 4 hours
|
The Borg-Dyspnea score measures an individual's effort, exertion, breathlessness and fatigue during physical work.
This scale ranges from 6-20 with 6 representing no exertion at all and 20 representing maximal exertion.
|
initial bronchodilator treatment to disposition, an average of 4 hours
|
Change in Heart Rate Baseline to Disposition
Time Frame: The initial bronchodilator treatment to to disposition, an average of 4 hours
|
Change in the heart rate at baseline after the initial bronchodilator treatment in the Aeroneb group compared to the small volume jet nebulizer group.
|
The initial bronchodilator treatment to to disposition, an average of 4 hours
|
Length of Stay in the ER
Time Frame: Length of stay in the ER - up to one day
|
Total length from admission to discharge.
|
Length of stay in the ER - up to one day
|
Percentage of Patients Requiring Hospitalization
Time Frame: Length of stay in the ER - up to one day
|
Total amount of patients requiring hospitalization after ER admission.
|
Length of stay in the ER - up to one day
|
The Total Dose of Albuterol Used in Each Group During ED Stay
Time Frame: Length of stay in the ER - up to one day
|
Albuterol is used to prevent and treat difficulty breathing, wheezing, shortness of breath, coughing, and chest tightness caused by lung diseases such as asthma and chronic obstructive pulmonary disease.
|
Length of stay in the ER - up to one day
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Total Dose of Ipratropium Used in Each Group During ED Stay
Time Frame: Length of stay in the ER - up to one day
|
Ipratropium is used to prevent wheezing, shortness of breath, coughing and chest tightness in people with chronic obstructive pulmonary disease, chronic bronchitis, and emphysema.
It is a bronchodilator which relaxes and opens the air passages to the lungs to make breathing easier.
|
Length of stay in the ER - up to one day
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nicholas S Hill, MD, Tufts Medical Center
Publications and helpful links
General Publications
- Borg G. Perceived exertion as an indicator of somatic stress. Scand J Rehabil Med. 1970;2(2):92-8. No abstract available.
- National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol. 2007 Nov;120(5 Suppl):S94-138. doi: 10.1016/j.jaci.2007.09.043. Erratum In: J Allergy Clin Immunol. 2008 Jun;121(6):1330.
- Patrick W, Webster K, Ludwig L, Roberts D, Wiebe P, Younes M. Noninvasive positive-pressure ventilation in acute respiratory distress without prior chronic respiratory failure. Am J Respir Crit Care Med. 1996 Mar;153(3):1005-11. doi: 10.1164/ajrccm.153.3.8630538.
- Galindo-Filho VC, Ramos ME, Rattes CS, Barbosa AK, Brandao DC, Brandao SC, Fink JB, de Andrade AD. Radioaerosol Pulmonary Deposition Using Mesh and Jet Nebulizers During Noninvasive Ventilation in Healthy Subjects. Respir Care. 2015 Sep;60(9):1238-46. doi: 10.4187/respcare.03667. Epub 2015 Jun 23.
- Ari A, Atalay OT, Harwood R, Sheard MM, Aljamhan EA, Fink JB. Influence of nebulizer type, position, and bias flow on aerosol drug delivery in simulated pediatric and adult lung models during mechanical ventilation. Respir Care. 2010 Jul;55(7):845-51.
- McFadden ER Jr. Acute severe asthma. Am J Respir Crit Care Med. 2003 Oct 1;168(7):740-59. doi: 10.1164/rccm.200208-902SO.
- Rodrigo G, Rodrigo C. A new index for early prediction of hospitalization in patients with acute asthma. Am J Emerg Med. 1997 Jan;15(1):8-13. doi: 10.1016/s0735-6757(97)90039-5.
- Rodrigo G, Rodrigo C. Early prediction of poor response in acute asthma patients in the emergency department. Chest. 1998 Oct;114(4):1016-21. doi: 10.1378/chest.114.4.1016.
- Piovesan DM, Menegotto DM, Kang S, Franciscatto E, Millan T, Hoffmann C, Pasin LR, Fischer J, Barreto SS, Dalcin Pde T. Early prognosis of acute asthma in the emergency room. J Bras Pneumol. 2006 Jan-Feb;32(1):1-9. doi: 10.1590/s1806-37132006000100004. English, Portuguese.
- Alvine GF, Rodgers P, Fitzsimmons KM, Ahrens RC. Disposable jet nebulizers. How reliable are they? Chest. 1992 Feb;101(2):316-9. doi: 10.1378/chest.101.2.316.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 11643 (DAIDS ES)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma Exacerbation
-
Poitiers University HospitalRecruitingModerate Asthma Exacerbation | Severe Asthma ExacerbationFrance
-
Parc de Salut MarRecruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
Khyber Teaching HospitalRecruitingChildhood Asthma With Acute ExacerbationPakistan
-
University of Massachusetts, WorcesterWithdrawn
-
Hannover Medical SchoolCompletedCommunity-acquired Pneumonia | Antimicrobial Stewardship | Exacerbation Copd | Lower Respiratory Tract and Lung Infections | Exacerbation of Allergic AsthmaGermany
-
Lawson Health Research InstituteCompletedAsthma ExacerbationCanada
-
Brian JacobsSiemens MedicalCompletedAsthma ExacerbationUnited States
-
Meir Medical CenterUnknown
-
University of East AngliaMerck Sharp & Dohme LLC; Norfolk Association of Asthma NursesCompleted
Clinical Trials on Small volume jet nebulizer
-
Cliniques universitaires Saint-Luc- Université...Unknown
-
Cliniques universitaires Saint-Luc- Université...Fonds National de la Recherche ScientifiqueUnknownAerosol Drug TherapyBelgium
-
Medstar Health Research InstituteWithdrawnChronic Obstructive Pulmonary DiseaseUnited States
-
Sultan Abdulhamid Han Training and Research Hospital...Recruiting
-
Philips RespironicsCompleted
-
Centre d'Investigation Clinique et Technologique...Unknown
-
Southeast University, ChinaCompleted
-
Universidade Federal de PernambucoCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional... and other collaboratorsCompleted
-
University of Texas Southwestern Medical CenterCompleted